Overview

PhII ICb With/Without Erbitux in MBC Pts

Status:
Active, not recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

US Oncology Research

Collaborators:

Bristol-Myers Squibb
Pfizer

Treatments:

Camptothecin
Carboplatin
Cetuximab
Irinotecan